QC
ROIV icon

Quantessence Capital’s Roivant Sciences ROIV Stock Holding History

Quantessence Capital’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,513
Closed -$126K – 395
2025
Q1 		$126K Buy
+12,513
New +$135K 0.03% 298

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Quantessence Capital's ROIV Position: Q2 2025 in Review

Quantessence Capital sold out of Roivant Sciences (ROIV) in Q2 2025, closing a stake of 12,513 shares — an estimated $126K sold.

Quantessence Capital first reported a position in ROIV in Q1 2025 and held it in 1 quarter. The position peaked at $126K in Q1 2025. 337 funds tracked by Wall St. Rank hold ROIV as of Q2 2025.

  • Quantessence Capital reported no remaining Roivant Sciences position as of Q2 2025 after selling out during the quarter.
  • Quantessence Capital sold 12,513 Roivant Sciences shares in Q2 2025, an estimated $126K.
  • Quantessence Capital first reported a position in Roivant Sciences in Q1 2025 and held it in 1 quarter.
  • Quantessence Capital's Roivant Sciences position peaked at $126K in Q1 2025.
  • 337 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2025.

Based on Quantessence Capital's 13F filing for Q2 2025, filed 14 Aug 2025.